NeuroQuest’s New Biomarker Technology Soon Coming to SC

An Israeli start-up company developing biomarkers for early detection of ALS and Alzheimer’s disease (AD) will establish its clinical development base in Charleston, South Carolina. NeuroQuest’s blood- based biomarker technology is based on the research of Michal Schwartz at the Weizmann Institute of Science, which identified cellular components of the immune system that are required for normal brain function. By measuring immune biomarkers in patients’ blood, NeuroQuest’s technology can recognize neurodegenerative disease-specific immune responses at their early stages. In initial trials, the biomarker demonstrated up to 85% diagnostic accuracy for both AD and ALS. NeuroQuest recently closed two investment rounds with SCRA Technology Ventures.

An Israeli start-up company developing biomarkers for early detection of ALS and Alzheimer’s disease (AD) will establish its clinical development base in Charleston, South Carolina. NeuroQuest’s blood- based biomarker technology is based on the research of Michal Schwartz at the Weizmann Institute of Science, which identified cellular components of the immune system that are required for normal brain function. By measuring immune biomarkers in patients’ blood, NeuroQuest’s technology can recognize neurodegenerative disease-specific immune responses at their early stages. In initial trials, the biomarker demonstrated up to 85% diagnostic accuracy for both AD and ALS. NeuroQuest recently closed two investment rounds with SCRA Technology Ventures.

Click here to read more.

Share this:
Facebooktwittergoogle_plusmailFacebooktwittergoogle_plusmail